



In Re Application of: CHAIN, Daniel G.
Application No.: 09/402,820
Filed: October 12, 1999
For: RECOMBINANT ANTIBODIES SPECIFIC FOR A-AMYLOID ENDS, DNA ...

Art Unit: 1632
Examiner: D. Crouch
Washington, D.C.
Atty.'s Docket: CHAIN=1B
Date: March 14, 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a ☐ Amendment ☒ Response

in the above-identified application.

☐ Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

☒ No additional fee is required.

☐ The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	*	MINUS	** 20	0
INDEP.	*	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE TOTAL

SMALL ENTITY		
RATE		ADDITIONAL FEE
x 9		\$
x 40		\$
+ 135		\$
ADDITIONAL FEE TOTAL		\$

OTHER THAN SMALL ENTITY		
RATE		ADDITIONAL FEE
x 18		\$
x 80		\$
+ 270		\$
TOTAL		\$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- ☐ First - \$ 55.00
☐ Second - \$ 195.00
☐ Third - \$ 445.00
☐ Fourth - \$ 695.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

- ☐ First - \$ 110.00
☐ Second - \$ 390.00
☐ Third - \$ 890.00
☐ Fourth - \$ 1390.00

Month After Time Period Set

☐ Less fees (\$) already paid for month(s) extension of time on .

☐ Please charge my Deposit Account No. 02-4035 in the amount of \$.

☐ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$.

☐ A check in the amount of \$ is attached (check no.).

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

By: Roger L. Browdy
Roger L. Browdy
Registration No. 25,618

Allen Yum
Reg. No. 37,971

RECEIVED

MAR 15 2001

TECH CENTER 1600/2900



#9
3-19-01
p.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1632
)	
Daniel G. CHAIN)	Examiner:
)	
Appln. No.: 09/402,820)	Washington, D.C.
)	
Filed: October 12, 1999)	March 14, 2001
)	
For: RECOMBINANT ANTIBODIES)	Atty.Docket: CHAIN=1B
SPECIFIC FOR BETA-AMYLOID)	
ENDS, DNA ENCODING ...)	

RESPONSE

RECEIVED

MAR 15 2001

Honorable Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

The present communication is responsive to the official action of February 14, 2001. Claims 1-31 presently appear in this case. All of the claims have been subject to a restriction requirement. No claim has yet been examined on the merits. Prompt consideration on the merits is hereby respectfully urged.

The examiner has required restriction between the following two groups:

Group I, including claims 1-13, 15-22 and 26-31 drawn to methods of inhibiting or preventing Alzheimer's Disease comprising administering a DNA sequence encoding an antibody specific for the C- or N-terminus of an amyloid- β

peptide, the DNA sequence, vectors comprising the sequence, cells comprising the vector, and pharmaceutical compositions comprising the DNA sequence; and

Group II, including claims 14 and 23-25 drawn to antibodies.

Applicant hereby elects Group II including claims 14 and 23-25. Prompt consideration on the merits is hereby earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By Roger L. Browdy
Roger L. Browdy
Registration No. 25,618

RLB:al
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
E:\M\Mind\Chainlb\Pto\RestrictResponse.doc

by Allen Yun
Reg. No. 37,971